GILD
Gilead Sciences, Inc. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow -30.0% ·
net new positions +16.7%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 6 | +1 | 5.67M | $830.55M | +1 | n/a |
| Q2 2026 | 175 | +1 | 941.63M | $119.04B | +5 | −3 |
| Q1 2026 | 176 | +4 | 930.86M | $129.53B | +6 | −3 |
| Q4 2025 | 171 | 0 | 1.00B | $122.89B | +1 | n/a |
| Q3 2025 | 23 | -1 | 603.99M | $67.03B | n/a | −2 |
| Q2 2025 | 22 | -1 | 560.26M | $62.11B | n/a | −1 |
| Q1 2025 | 20 | 0 | 255.31M | $28.60B | n/a | n/a |
| Q4 2024 | 20 | +1 | 270.33M | $24.97B | +1 | n/a |
| Q3 2024 | 18 | 0 | 213.42M | $17.89B | n/a | n/a |
| Q2 2024 | 18 | n/a | 202.41M | $13.88B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Robeco Institutional Asset… | 3.44M | -0.5% | $513.15M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 2 | Assenagon Asset Management S.A. | 1.56M | -65.9% | $232.59M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wealth Enhancement Advisory… | 358.00K | -40.7% | $38.70M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 4 | TD Waterhouse Canada Inc. | 153.80K | -68.1% | $22.70M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 5 | Assetmark, Inc | 147.76K | +6.0% | $22.02M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Ninety One UK Ltd | 9.31K | New | $1.39M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Ninety One UK Ltd | $1.39M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 61.30K shares, $8,543 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.00K sh · $468,660
Officer · 3.00K sh · $468,660
Officer · 600 sh · $87,174
Officer · 800 sh · $115,566
Officer · 1.60K sh · $229,907
Officer · 3.00K sh · $435,870
Officer, Director · 1.60K sh · $236,014
Officer, Director · 7.99K sh · $1.19M
Officer, Director · 5.41K sh · $807,856
Director · 6.88K sh · $1.02M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology